Skip to content
Public health advocates are reevaluating the vaccine landscape, revisiting long-held assumptions about vaccine policy during both public health emergencies and periods of relative calm. […]
BIO 2025: How do we talk about vaccines now? Read More »
From drug discovery to clinical trials, AI is being used, studied, refined, and advanced as a means to slingshot biotech innovations into the future
BIO 2025: AI Summit highlights role of collaboration in reaching the next frontier Read More »
America, for decades, has been the undisputed global leader when it comes to innovative drug development. But this leadership is now at risk. “We
BIO Coffee Chat: ORPHAN Cures Act key to fighting rare disease Read More »
In April 2025, the Department of Health and Human Services (HHS) announced it would disband the Advisory Committee on Heritable Disorders in Newborns and
Patient’s mother advocates for newborn screening program reform Read More »
May is Arthritis Awareness Month, and in observance, Bio.News asked AiArthritis to discuss how it is advancing the needs of patients with autoimmune and
Arthritis Awareness Month: AiArthritis puts a focus on patients Read More »
Starting and running a patient advocacy organization is a massive undertaking. It often includes fundraising, standing up and operating a board and non-profit structure,
BIO Coffee Chat offers advice on launching a successful patient advocacy organization Read More »
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s “MAHA Report: Make Our Children Healthy Again,” released May 22, identifies the Trump administration’s
MAHA report takes issue with industry-funded research Read More »
America has long been the global leader in rare disease drug development but this leadership is at risk unless Congress protects key incentives In
U.S. leadership in rare disease drugs at risk, BIO expert tells Orphan Drug Congress Read More »
State legislatures remain busy across the country—especially when it comes to healthcare policy. As Q1 wraps up and we move into the mid-year, the
Q1 roundup of state health policy impacting biotech Read More »
Agricultural legislative activity is proving to be busy this year for biotech as we move out of Q1 and into the summer. GMO labeling,
Q1 roundup of state ag policy impacting biotech Read More »
